UCB S.A.-Product Pipeline Review-2015

UCB S.A.-Product Pipeline Review-2015

  • Products Id :- GMDHC06955CDB
  • |
  • Pages: 90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

UCB S.A.-Product Pipeline Review-2015


Global Markets Direct's, 'UCB S.A.-Product Pipeline Review-2015', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of UCB S.A.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the UCB S.A.'s pipeline products

Reasons To Buy

Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of UCB S.A. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the UCB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

UCB S.A. Snapshot 6

UCB S.A. Overview 6

Key Information 6

Key Facts 6

UCB S.A.-Research and Development Overview 7

Key Therapeutic Areas 7

UCB S.A.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

UCB S.A.-Pipeline Products Glance 16

UCB S.A.-Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

UCB S.A.-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

UCB S.A.-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

UCB S.A.-Drug Profiles 22

brivaracetam 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

certolizumab pegol 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

levetiracetam 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

epratuzumab 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

lacosamide 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

rotigotine 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

bimekizumab 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

dapirolizumab pegol 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

UCB-0942 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

UCB-5857 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

UCB-7665 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Antibodies for Cancer, Immunology and Inflammation 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

VR-942 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Antibodies for Diabetes and Metabolic Disorders 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Antibody to Inhibit Transglutaminase 2 for Fibrosis 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

UCB S.A.-Pipeline Analysis 58

UCB S.A.-Pipeline Products by Target 58

UCB S.A.-Pipeline Products by Route of Administration 60

UCB S.A.-Pipeline Products by Molecule Type 61

UCB S.A.-Pipeline Products by Mechanism of Action 62

UCB S.A.-Recent Pipeline Updates 63

UCB S.A.-Dormant Projects 79

UCB S.A.-Discontinued Pipeline Products 80

Discontinued Pipeline Product Profiles 80

CDP-323 80

CDP-435 80

CDP-484 81

CDP-860 81

lacosamide 81

seletracetam 81

UCB-2892 81

WX-037 82

WX-554 82

UCB S.A.-Company Statement 83

UCB S.A.-Locations And Subsidiaries 84

Head Office 84

Other Locations & Subsidiaries 84

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Tables

UCB S.A., Key Information 6

UCB S.A., Key Facts 6

UCB S.A.-Pipeline by Indication, 2015 9

UCB S.A.-Pipeline by Stage of Development, 2015 10

UCB S.A.-Monotherapy Products in Pipeline, 2015 11

UCB S.A.-Partnered Products in Pipeline, 2015 12

UCB S.A.-Partnered Products/ Combination Treatment Modalities, 2015 13

UCB S.A.-Out-Licensed Products in Pipeline, 2015 14

UCB S.A.-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

UCB S.A.-Pre-Registration, 2015 16

UCB S.A.-Phase III, 2015 17

UCB S.A.-Phase II, 2015 18

UCB S.A.-Phase I, 2015 19

UCB S.A.-Preclinical, 2015 20

UCB S.A.-Discovery, 2015 21

UCB S.A.-Pipeline by Target, 2015 59

UCB S.A.-Pipeline by Route of Administration, 2015 60

UCB S.A.-Pipeline by Molecule Type, 2015 61

UCB S.A.-Pipeline Products by Mechanism of Action, 2015 62

UCB S.A.-Recent Pipeline Updates, 2015 63

UCB S.A.-Dormant Developmental Projects,2015 79

UCB S.A.-Discontinued Pipeline Products, 2015 80

UCB S.A., Subsidiaries 84

List of Figures

UCB S.A.-Pipeline by Top 10 Indication, 2015 8

UCB S.A.-Pipeline by Stage of Development, 2015 10

UCB S.A.-Monotherapy Products in Pipeline, 2015 11

UCB S.A.-Partnered Products in Pipeline, 2015 12

UCB S.A.-Out-Licensed Products in Pipeline, 2015 14

UCB S.A.-Pipeline by Top 10 Target, 2015 58

UCB S.A.-Pipeline by Top 10 Route of Administration, 2015 60

UCB S.A.-Pipeline by Top 10 Molecule Type, 2015 61

UCB S.A.-Pipeline Products by Top 10 Mechanism of Action, 2015 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of UCB S.A.; UCB S.A. - Key Therapeutics; UCB S.A. - Pipeline Overview and Promising Molecules; UCB S.A. - News; UCB S.A. - Latest Updates; UCB S.A. - Pipeline; UCB S.A. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107670
Site License
USD 3000 INR 215340
Corporate User License
USD 4500 INR 323010



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com